Health Discovery Corporation (OTCBB: HDVY), the molecular diagnostics company that recently launched MelApp, the first SVM-based image analysis iPhone app for melanoma risk assessment, reports great adoption among consumers with nearly 5000 downloads across 48 countries in just its first two months on the market with the second month growth rate being more than 35% higher than the first month. Pleased with the interest from consumers and the medical community to date, Health Discovery is now preparing to release a version of MelApp for the increasingly popular Android operating system expected around the first week of October.
“It’s incredibly exciting to see our advanced mathematical techniques used in this manner, but more so, to see the volume of downloads after only an initial soft launch of the MelApp. The initial success of MelApp exceeds our expectations,” said Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. “Management is quite pleased with the initial volume of downloads and is committed to MelApp’s next stage of growth with an improved iPhone update and the forthcoming Android application. Once the Android version of MelApp is launched, the Company plans a much more aggressive international marketing program and expects downloads to increase significantly in the upcoming months.”
Launched this summer, MelApp uses highly sophisticated patent protected mathematical algorithms and image based pattern recognition technology to analyze an uploaded image. The app was validated using an image database licensed from Johns Hopkins University Medical Center and uses the iPhone camera feature to deliver a risk analysis of user’s photographed skin lesions within seconds. In addition, MelApp can use the iPhone GPS to refer users to physicians specializing in the diagnosis and treatment of melanoma for proper medical follow-up.
“We are also quite pleased with the number of both academic and private practice U.S. and International physicians specializing in melanoma diagnosis and treatment that have requested to be part of our subscribed physician referral network.” Dr. Barnhill adds, "It has been hugely rewarding to recently hear of a patient being diagnosed with early stage melanoma after being referred to a physician by MelApp."
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts